LEADER 00861nam0-22003131i-450- 001 990007872280403321 005 20160330113534.0 010 $a0-471-97705-5 035 $a000787228 035 $aFED01000787228 035 $a(Aleph)000787228FED01 035 $a000787228 100 $a20040422d1999----km-y0itay50------ba 101 0 $aeng 102 $aGB 105 $ay---j---001y- 200 1 $aBasic molecular biology$eessential techniques$fPhilippa D. Darbre 210 $aChichester$cWiley$dc1999 225 1 $aEssential techniques series 610 0 $aBiologia molecolare 676 $a574.88 700 1$aDarbre,$bPhilippa D.$0282222 801 0$aIT$bUNINA$gRICA$2UNIMARC 901 $aBK 912 $a990007872280403321 952 $a60 574.88 B 18$b9339$fFAGBC 959 $aFAGBC 996 $aBasic molecular biology$9672967 997 $aUNINA LEADER 02339nas 22006253a 450 001 996417405903316 005 20221206200943.0 011 $a2166-3971 035 $a(OCoLC)51055948 035 $a(CKB)110979839329271 035 $a(CONSER)--2012202646 035 $a(EXLCZ)99110979839329271 100 $a20021122a19769999 s-- a 101 0 $aeng 135 $aurun||||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 14$aThe Food & drug letter 210 $a[Arlington, VA] $cWashington Business Information 300 $a"The Food & Drug Letter provides reliable, in-depth analysis of how FDA's regulations and procedures will affect your current decisions and long-term plans and gives you in-depth interpretation to tell you why FDA is making or proposing revisions. Helps you chart your course for electronic signatures, drug and device GMPs, labeling, FDA inspections and much more."--FDANews Newsletters homepage, viewed November 11, 2002 311 $a0362-6466 517 3 $aFood and drug letter 517 1 $aFDANews.com 517 1 $aFDANews 517 1 $aFDA news 517 1 $aFood and Drug Administration news 517 1 $aDrugs, medical devices, & biologics news and FDAnews.com 531 $aFOOD AND DRUG LETTER 531 $aTHE FOOD AND DRUG LETTER 531 $aFOOD & DRUG LETTER 606 $aFood law and legislation$vPeriodicals 606 $aDrugs$xLaw and legislation$vPeriodicals 606 $aUnited States Food and Drug Administration 606 $aFood 606 $aLegislation, Drug 606 $aDrugs$xLaw and legislation$2fast$3(OCoLC)fst00898830 606 $aFood law and legislation$2fast$3(OCoLC)fst00930954 608 $aPeriodical 608 $aLegislation$vPeriodicals. 608 $aPeriodicals.$2fast 608 $aPeriodicals.$2lcgft 610 $aAgricultural Economics 615 0$aFood law and legislation 615 0$aDrugs$xLaw and legislation 615 2$aUnited States Food and Drug Administration 615 2$aFood 615 2$aLegislation, Drug 615 7$aDrugs$xLaw and legislation. 615 7$aFood law and legislation. 676 $a344 906 $aJOURNAL 912 $a996417405903316 996 $aThe Food & drug letter$92579377 997 $aUNISA LEADER 05516nam 22005775 450 001 9910253931103321 005 20251116182830.0 010 $a3-319-47266-6 024 7 $a10.1007/978-3-319-47266-9 035 $a(CKB)3710000001410438 035 $a(DE-He213)978-3-319-47266-9 035 $a(MiAaPQ)EBC4882070 035 $a(Au-PeEL)EBL4882070 035 $a(CaPaEBR)ebr11399843 035 $a(OCoLC)991571145 035 $a(PPN)202993094 035 $a(EXLCZ)993710000001410438 100 $a20170620d2017 u| 0 101 0 $aeng 135 $aurnn#008mamaa 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aAntimicrobial Drug Resistance $eClinical and Epidemiological Aspects, Volume 2 /$fedited by Douglas L. Mayers, Jack D. Sobel, Marc Ouellette, Keith S. Kaye, Dror Marchaim 205 $a2nd ed. 2017. 210 1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2017. 215 $a1 online resource (XXI, 855 p. 61 illus., 32 illus. in color.) 311 08$a3-319-47264-X 327 $aHistory of Drug-Resistant Microbes -- Evolutionary Biology of Drug Resistance -- Pharmacology of Drug Resistance -- Drug Development for Drug-Resistant Pathogens -- Genetic Mechanisms of Transfer of Drug Resistance -- Mutations as a Basis of Antimicrobial Resistance -- Altered Drug Targets -- Enzymatic Modification of Drugs -- Reduced Drug Penetration -- Active Efflux Mechanism -- Biofilms -- Beta-Lactamases -- Penicillin Binding Proteins -- Aminoglycosides -- Tetracyclines and ChloramphenicolQuinolones -- Plasmid Mediated Quinolone Resistance to Macrolides, Lincosamides, and Streptogramins -- Mechanisms of Resistance in Metronidazole -- Glycopeptide-resistance in eneterococci -- Daptomycin Resistance -- Oxazolidinones -- PolymyxinsSulfonamides and Trimethoprim -- Antimycobacterial Agents -- Amphotericin (Polyenes) -- Azoles -- Flucytosine -- Echinocandins -- Antifungal Targets, Mechanisms of Action, and Resistance in Candida albicans -- Herpes Nucleoside Drugs -- Influenza Drugs -- HIV Nucleoside Drugs -- HIV Non-Nucleoside Drugs -- HIV Protease Inhibitors -- HIV Entry Inhibitors -- HIV Integrase Inhibitors -- Hepatitis B -- Hepatitis C -- Agents for anaerobic protozoa -- Antimalarial Agents -- Agents for Leishmania -- Agents for Trypanosomes -- Agents for Toxoplasma -- Agents for Cryptosporidium -- Agents against Nematodes -- Agents against Trematodes and Cestodes -- Agents against Ectoparasites. 330 $aThe two volumes included in Antimicrobial Drug Resistance, Second Edition is an updated, comprehensive and multidisciplinary reference covering the area of antimicrobial drug resistance in bacteria, fungi, viruses, and parasites from basic science, clinical, and epidemiological perspectives. This newly revised compendium reviews the most current research and development on drug resistance while still providing the information in the accessible format of the first edition. The first volume, Antimicrobial Drug Resistance: Mechanisms of Drug Resistance, is dedicated to the biological basis of drug resistance and effective avenues for drug development. With the emergence of more drug-resistant organisms, the approach to dealing with the drug resistance problem must include the research of different aspects of the mechanisms of bacterial resistance and the dissemination of resistance genes as well as research utilizing new genomic information. These approaches will permit the design of novel strategies to develop new antibiotics and preserve the effectiveness of those currently available. The second volume, Antimicrobial Drug Resistance: Clinical and Epidemiological Aspects, is devoted to the clinical aspects of drug resistance. Although there is evidence that restricted use of a specific antibiotic can be followed by a decrease in drug resistance to that agent, drug resistance control is not easily achieved. Thus, the infectious diseases physician requires input from the clinical microbiologist, antimicrobial stewardship personnel, and infection control specialist to make informed choices for the effective management of various strains of drug-resistant pathogens in individual patients. This 2-volume set is an important reference for students in microbiology, infectious diseases physicians, medical students, basic scientists, drug development researchers, microbiologists, epidemiologists, and public health practitioners. 606 $aDrug resistance 606 $aInfectious diseases 606 $aDrug Resistance$3https://scigraph.springernature.com/ontologies/product-market-codes/B16020 606 $aInfectious Diseases$3https://scigraph.springernature.com/ontologies/product-market-codes/H33096 615 0$aDrug resistance. 615 0$aInfectious diseases. 615 14$aDrug Resistance. 615 24$aInfectious Diseases. 676 $a616.9041 702 $aMayers$b Douglas L$4edt$4http://id.loc.gov/vocabulary/relators/edt 702 $aSobel$b Jack D$4edt$4http://id.loc.gov/vocabulary/relators/edt 702 $aOuellette$b Marc$4edt$4http://id.loc.gov/vocabulary/relators/edt 702 $aKaye$b Keith S.$4edt$4http://id.loc.gov/vocabulary/relators/edt 702 $aMarchaim$b Dror$4edt$4http://id.loc.gov/vocabulary/relators/edt 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910253931103321 996 $aAntimicrobial Drug Resistance$91910240 997 $aUNINA